However, since the impact of IL33 inhibition on animal survival was not tested here, future testing using in vivo mouse models will be needed before considering reagents such as IL33-blocking antibody ANB020, as a possible therapy in DIPG cases. The gene discussed is IL33; the disease is diffuse intrinsic pontine glioma.